JP2013526523A5 - - Google Patents

Download PDF

Info

Publication number
JP2013526523A5
JP2013526523A5 JP2013510209A JP2013510209A JP2013526523A5 JP 2013526523 A5 JP2013526523 A5 JP 2013526523A5 JP 2013510209 A JP2013510209 A JP 2013510209A JP 2013510209 A JP2013510209 A JP 2013510209A JP 2013526523 A5 JP2013526523 A5 JP 2013526523A5
Authority
JP
Japan
Prior art keywords
dosage form
patent document
weight
granules
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013510209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526523A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/035770 external-priority patent/WO2011143120A1/en
Publication of JP2013526523A publication Critical patent/JP2013526523A/ja
Publication of JP2013526523A5 publication Critical patent/JP2013526523A5/ja
Pending legal-status Critical Current

Links

JP2013510209A 2010-05-11 2011-05-09 メトプロロールを含むアルコール耐性持続放出性経口剤形 Pending JP2013526523A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33353110P 2010-05-11 2010-05-11
US61/333,531 2010-05-11
PCT/US2011/035770 WO2011143120A1 (en) 2010-05-11 2011-05-09 Alcoholres i stant metoprolol - containing extended - release oral dosage forms

Publications (2)

Publication Number Publication Date
JP2013526523A JP2013526523A (ja) 2013-06-24
JP2013526523A5 true JP2013526523A5 (enExample) 2014-06-26

Family

ID=44478710

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013510209A Pending JP2013526523A (ja) 2010-05-11 2011-05-09 メトプロロールを含むアルコール耐性持続放出性経口剤形

Country Status (6)

Country Link
US (1) US8927025B2 (enExample)
EP (1) EP2568977A1 (enExample)
JP (1) JP2013526523A (enExample)
CA (1) CA2798702A1 (enExample)
MX (1) MX2012012991A (enExample)
WO (1) WO2011143120A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2512456A2 (en) * 2009-12-17 2012-10-24 Cima Labs Inc. Abuse-resistant formulations
DK3164117T3 (da) 2014-07-03 2023-12-04 SpecGx LLC Misbrugssikre formuleringer med øjeblikkelig frigivelse omfattende ikke-cellulose-polysaccharider
US20180344649A1 (en) 2015-09-29 2018-12-06 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US11478426B2 (en) 2018-09-25 2022-10-25 SpecGx LLC Abuse deterrent immediate release capsule dosage forms

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187703B1 (en) 1985-01-11 1992-08-05 Teijin Limited Sustained release preparation
US4863456A (en) 1986-04-30 1989-09-05 Alza Corporation Dosage form with improved delivery capability
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4873092A (en) 1987-05-21 1989-10-10 Murata Kikai Kabushiki Kaisha Slow-releasing preparation
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5403593A (en) 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
TW209174B (enExample) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
DE69229881T2 (de) 1991-10-04 1999-12-09 Yoshitomi Pharmaceutical Industries, Ltd. Tablette mit verzögerter freisetzung
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
IT1264020B (it) 1993-01-28 1996-09-09 Recordati Chem Pharm Procedimento per la preparazione di microgranuli idonei alla sospensione in liquidi
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
SE9301057L (sv) 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
AU2068797A (en) 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
WO1997032573A1 (en) 1996-03-08 1997-09-12 Nycomed Danmark A/S Modified release multiple-units dosage composition
JP3511042B2 (ja) 1996-06-28 2004-03-29 ソニー株式会社 ヒートシュリンクバンド用鋼板
US20020110595A1 (en) 1996-06-28 2002-08-15 Basf Corporation Slow release pharmaceutical compositions
ATE292456T1 (de) 1996-09-13 2005-04-15 Shionogi & Co Zubereitung mit verlängerter freisetzung unter verwendung einer thermischen umwandlung sowie verfahren zu deren herstellung
FR2753904B1 (fr) 1996-10-01 1998-10-30 Gattefosse Ets Sa Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication
US6375987B1 (en) 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
BE1011045A3 (fr) 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US5904927A (en) 1997-03-14 1999-05-18 Northeastern University Drug delivery using pH-sensitive semi-interpenetrating network hydrogels
PT1015352E (pt) 1997-04-01 2007-09-24 Cima Labs Inc ''embalagem alveolar e comprimidos embalados''
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5851555A (en) 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US20040028735A1 (en) 1997-11-14 2004-02-12 Unchalee Kositprapa Pharmaceutical formulation
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
DK1126826T6 (en) 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
US7767708B2 (en) 1998-11-04 2010-08-03 Schering-Plough Animal Health Corp. Growth stimulant compositions
PE20001396A1 (es) 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
DE19901687B4 (de) 1999-01-18 2006-06-01 Grünenthal GmbH Opioide Analgetika mit kontrollierter Wirkstofffreisetzung
PT1146861E (pt) 1999-02-03 2005-10-31 Powderject Res Ltd Formulacoes de particulas de hidrogel
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6680071B1 (en) 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
ES2213949T3 (es) 1999-07-02 2004-09-01 Cognis Iberia, S.L. Microcapsulas i.
EP1064913B1 (de) 1999-07-02 2005-09-14 Cognis IP Management GmbH Mikrokapseln - III
DE19932603A1 (de) 1999-07-13 2001-01-25 Gruenenthal Gmbh Wirkstoffhaltiger Mehrschichtfilm aus in situ vernetzten hydrophilen Polymeren
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
SE9903236D0 (sv) 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
EP2003134B1 (en) 1999-11-09 2011-03-02 Abbott Laboratories Hydromorphinone compositions
ES2539904T3 (es) 2000-02-08 2015-07-07 Euro-Celtique S.A. Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． ヒドロコドン放出制御製剤
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CA2446738C (en) 2001-05-11 2012-05-29 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
AU2002314968B2 (en) 2001-06-08 2006-12-07 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
JP4848101B2 (ja) 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US20040052843A1 (en) 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
KR100540035B1 (ko) 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
DE60325567D1 (de) 2002-04-05 2009-02-12 Euro Celtique Sa Matrix für die modifizierte freigabe von aktiven substanzen
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
AU2003247876B2 (en) 2002-07-05 2006-10-05 Collegium Pharmaceutical, Inc Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040208936A1 (en) 2002-07-22 2004-10-21 Roland Chorin Novel compositions
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20050266072A1 (en) 2002-08-15 2005-12-01 Euro-Celtique S.A. Pharmaceutical compositions
US20040052844A1 (en) 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
CA2499550C (en) 2002-09-20 2013-10-15 Alpharma, Inc. Sequestering subunit and related compositions and methods
US20050020613A1 (en) 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
WO2004026262A2 (en) 2002-09-23 2004-04-01 Verion, Inc. Abuse-resistant pharmaceutical compositions
WO2004045551A2 (en) 2002-11-15 2004-06-03 Branded Products For The Future Pharmaceutical composition
US7910128B2 (en) 2003-01-03 2011-03-22 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
WO2004064807A1 (en) 2003-01-23 2004-08-05 Amorepacific Corporation Sustained-release preparations and method for producing the same
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
DE602004024963D1 (de) 2003-03-13 2010-02-25 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
EP1782834A3 (en) 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
CA2518734A1 (en) 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
ATE495732T1 (de) 2003-03-26 2011-02-15 Egalet As Morphin-system mit kontrollierter freisetzung
SE0300831D0 (sv) 2003-03-26 2003-03-26 Pharmacia Ab New formulations and use therof
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
CA2519556C (en) 2003-04-21 2011-01-18 Benjamin Oshlack Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
IN2003MU00504A (enExample) 2003-06-05 2005-05-13 Alembic Ltd
US20050053656A1 (en) 2003-09-05 2005-03-10 Ping Jeffrey H. Compositions and methods for treating pain
US20090304793A1 (en) 2003-09-22 2009-12-10 Alpharma, Inc. Sustained release opioid formulations and methods of use
WO2005030181A1 (en) 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
WO2005034859A2 (en) 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
HUP0303382A2 (hu) 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
EP1689373B1 (en) 2003-10-10 2019-04-03 Ethypharm Sustained-release microgranules containing ginkgo biloba extract and the process for manufacturing these
ME01300B (me) 2003-12-31 2013-12-20 Cima Labs Inc Uglavnom linearne efervescentne oralne dozne forme fentanila i metode davanja
US20050165038A1 (en) 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
GB0408308D0 (en) 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
US20060024361A1 (en) 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US20070231268A1 (en) 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060263429A1 (en) 2005-05-20 2006-11-23 Hengsheng Feng Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof
US20070009589A1 (en) * 2005-07-07 2007-01-11 Kandarapu Raghupathi Extended release compositions
CN101257894A (zh) 2005-07-07 2008-09-03 法纳姆公司 高水溶性药物的缓释药物组合物
US20070092573A1 (en) * 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
FR2898056B1 (fr) 2006-03-01 2012-01-20 Ethypharm Sa Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
US20070212414A1 (en) 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
WO2007112574A1 (en) 2006-04-03 2007-10-11 Isa Odidi Extended release composition of venlafaxine
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
WO2008140460A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
DK2200593T5 (en) * 2007-09-13 2016-12-12 Cima Labs Inc Hog-resistant pharmaceutical formulation
CN101801357B (zh) 2007-09-21 2013-08-07 赢创罗姆有限公司 耐受乙醇的影响的pH依赖性受控释放的药物组合物
ATE455538T1 (de) 2007-11-09 2010-02-15 Acino Pharma Ag Retardtabletten mit hydromorphon
JP5827123B2 (ja) 2008-09-16 2015-12-02 ウェルズ ファーゴ バンク ナショナル アソシエイション 乱用の可能性が低いｐｅｇ化オピオイド

Similar Documents

Publication Publication Date Title
JP2013526521A5 (enExample)
JP5894720B2 (ja) アルコール抵抗性製剤
JP6772430B2 (ja) テソフェンシンとベータブロッカーの合剤
TWI747810B (zh) 特別用於治療注意力缺失症之方法及組成物
CN101022788A (zh) 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
CN105431144A (zh) 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
TW201004615A (en) Preparation of controlled release skeletal muscle relaxant dosage forms
CN102639117A (zh) 1-[2-(2,4-二甲基-苯基硫基)-苯基]哌嗪的新组合物
JP2013526523A5 (enExample)
WO2013020416A1 (zh) 伊伐布雷定或其可药用盐的缓释制剂
CN103717223A (zh) 含甘磷酸胆碱或者其药学上可接受的盐的缓释药物组合物及其制造方法
CN113018273B (zh) 一种固体制剂及其制备方法和用途
JP5545952B2 (ja) 徐放性製剤及びその製造方法
WO2025097792A1 (zh) 一种卡左双多巴三层片及其制备方法
JP2013526522A5 (enExample)
WO2017107768A1 (zh) 阿普斯特缓释制剂
CA2798702A1 (en) Alcoholresistant metoprolol-containing extended-release oral dosage forms
CN106456640A (zh) 色瑞替尼制剂
CN101584683A (zh) 美托拉宗缓释胶囊及其制备方法
JP2008542394A (ja) 少なくとも１つの形態のベンラファキシンの調節放出性組成物
CN115707455B (zh) 允许睡眠调节类药物分段释放的片剂及其制备方法
CN101756981B (zh) 一种布洛氯雷伪麻缓释制剂及其制备方法
CA2798701A1 (en) Alcohol-resistant extended release dosage forms comprising venlafaxine
CN105106963B (zh) 马来酸曲美布汀缓释制剂及其制备方法
CN103768068B (zh) 一种波生坦药物组合物